By using this cut score, the size of the IGF2-high group approximates the fraction of ovarian cancer patients expected to have intrinsically drug resistant tumors, manifested by progression during or shortly after completing chemotherapy. The gene discussed is IGF2; the disease is ovarian carcinoma.